A

AFT Pharmaceuticals Ltd
NZX:AFT

Watchlist Manager
AFT Pharmaceuticals Ltd
NZX:AFT
Watchlist
Price: 2.84 NZD 1.43% Market Closed
Market Cap: 297.8m NZD
Have any thoughts about
AFT Pharmaceuticals Ltd?
Write Note
AFT
/
Income Statement
/
EPS (Diluted)

AFT Pharmaceuticals Ltd
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

AFT Pharmaceuticals Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
A
AFT Pharmaceuticals Ltd
NZX:AFT
EPS (Diluted)
NZ$0
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
BLIS Technologies Ltd
NZX:BLT
EPS (Diluted)
NZ$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cannasouth Ltd
NZX:CBD
EPS (Diluted)
NZ$0
CAGR 3-Years
-10%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
Rua Bioscience Ltd
NZX:RUA
EPS (Diluted)
NZ$0
CAGR 3-Years
-33%
CAGR 5-Years
-48%
CAGR 10-Years
N/A
G
Greenfern Industries Ltd
NZX:GFI
EPS (Diluted)
NZ$0
CAGR 3-Years
59%
CAGR 5-Years
13%
CAGR 10-Years
N/A
No Stocks Found

AFT Pharmaceuticals Ltd
Glance View

Market Cap
297.8m NZD
Industry
Pharmaceuticals

AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. The firm's segments include New Zealand, Australia, Asia and Rest of World. The firm's products include Crystaderm, Maxigesic, Coco-scalp, Maxiclear, RestoraNail and Myconail, among others. The firm's NasoSURF Nebuliser is in pilot scale production. The firm is focused on conducting clinical for Maxigesic oral dose forms. The firm is also conducting clinical trials of Maxigesic intravenous (IV). Maxigesic PE is a cold and flu variant. Its subsidiary, AFT Pharmaceuticals (AU) Pty Ltd, is engaged in distribution of pharmaceuticals in Australia. Its subsidiary, AFT Pharmaceuticals Singapore Pte Ltd, is engaged in the registration of pharmaceuticals in Singapore. Its subsidiary, AFT Pharmaceuticals (S.E. Asia) Sdn Bhd, is engaged in the distribution of pharmaceuticals in Malaysia.

AFT Intrinsic Value
4.72 NZD
Undervaluation 40%
Intrinsic Value
Price
A
What is Intrinsic Value?

See Also

What is AFT Pharmaceuticals Ltd's EPS (Diluted)?
EPS (Diluted)
0.1 NZD

Based on the financial report for Sep 30, 2024, AFT Pharmaceuticals Ltd's EPS (Diluted) amounts to 0.1 NZD.

What is AFT Pharmaceuticals Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
0%

Over the last year, the EPS (Diluted) growth was 0%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.